Analysts Set Immunome, Inc. (NASDAQ:IMNM) Target Price at $27.17

Shares of Immunome, Inc. (NASDAQ:IMNM) have been assigned a consensus recommendation of “Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $27.17.

A number of analysts recently weighed in on IMNM shares. Wedbush reaffirmed an “outperform” rating and set a $33.00 target price on shares of Immunome in a report on Monday, March 10th. Lifesci Capital assumed coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target for the company.

Insider Activity

In other news, CEO Clay B. Siegall purchased 150,000 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the acquisition, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at $5,189,679. This represents a 28.87 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 8.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Immunome

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMNM. BNP Paribas Financial Markets bought a new stake in Immunome during the 4th quarter valued at $70,000. KLP Kapitalforvaltning AS purchased a new position in Immunome during the 4th quarter valued at about $75,000. AlphaQuest LLC lifted its position in Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock valued at $84,000 after acquiring an additional 7,867 shares during the period. Tower Research Capital LLC TRC lifted its position in Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock valued at $91,000 after acquiring an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC purchased a new position in Immunome during the 4th quarter valued at about $95,000. 44.58% of the stock is currently owned by institutional investors.

Immunome Trading Up 3.1 %

Immunome stock opened at $9.04 on Tuesday. The firm’s 50 day simple moving average is $9.93 and its 200 day simple moving average is $11.71. The firm has a market capitalization of $721.18 million, a PE ratio of -1.11 and a beta of 1.93. Immunome has a 1-year low of $8.39 and a 1-year high of $26.70.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.